A Rare Case Report of Tropheryma Whipplei-Induced Acute Respiratory Distress Syndrome in an Immunocompetent Patient
- PMID: 40657275
- PMCID: PMC12255247
- DOI: 10.2147/IDR.S530544
A Rare Case Report of Tropheryma Whipplei-Induced Acute Respiratory Distress Syndrome in an Immunocompetent Patient
Abstract
Tropheryma whipplei is a rare gram-positive bacterium traditionally associated with Whipple's disease, primarily presenting with gastrointestinal symptoms. Pulmonary involvement, particularly acute respiratory distress syndrome (ARDS), is extremely rare and poses diagnostic challenges, especially in immunocompetent individuals. We report a rare case of ARDS caused by Tropheryma whipplei in a 28-year-old immunocompetent male with no significant medical history. Traditional diagnostic methods failed to identify the causative pathogen. However, metagenomic next-generation sequencing (mNGS) of bronchoalveolar lavage fluid enabled rapid and accurate detection of T. whipplei, allowing timely initiation of targeted antimicrobial therapy with ceftriaxone and trimethoprim-sulfamethoxazole. The patient demonstrated marked clinical improvement and was discharged with no relapse at follow-up. This case highlights the critical diagnostic value of mNGS in atypical ARDS cases and emphasizes the importance of considering T. whipplei in the differential diagnosis, even among immunocompetent individuals.
Keywords: Tropheryma whipplei; acute respiratory distress syndrome; next-generation sequencing; rare infection; whipple’s disease.
© 2025 Fu et al.
Conflict of interest statement
The authors declare that they have no competing interests in this work.
Figures
Similar articles
-
Diagnosis of Tropheryma whipplei pneumonia in an immunocompromised lymphoma patient using metagenomic next generation sequencing: A case report.J Infect Chemother. 2025 Aug;31(8):102752. doi: 10.1016/j.jiac.2025.102752. Epub 2025 Jun 10. J Infect Chemother. 2025. PMID: 40505965
-
Oral treatment of Whipple's disease with doxycycline and hydroxychloroquine versus intravenous therapy with ceftriaxone followed by oral trimethoprim-sulfamethoxazole in Germany: a phase 2/3, prospective, open-label, randomised, controlled, non-inferiority trial.Lancet Infect Dis. 2025 Jul;25(7):788-800. doi: 10.1016/S1473-3099(24)00797-7. Epub 2025 Feb 17. Lancet Infect Dis. 2025. PMID: 39978372 Clinical Trial.
-
Systematic review: Whipple's disease (Tropheryma whipplei infection) and its unmasking by tumour necrosis factor inhibitors.Aliment Pharmacol Ther. 2015 Apr;41(8):709-24. doi: 10.1111/apt.13140. Epub 2015 Feb 19. Aliment Pharmacol Ther. 2015. PMID: 25693648
-
Rapidly progressive dementia and intractable diarrhea: a teaching case report and a systematic review of cognitive impairment in Whipple's disease.Neurol Sci. 2022 Feb;43(2):907-926. doi: 10.1007/s10072-021-05844-5. Epub 2022 Jan 3. Neurol Sci. 2022. PMID: 34981284 Free PMC article.
-
Tropheryma whipplei: a common bacterium in rural Senegal.PLoS Negl Trop Dis. 2011 Dec;5(12):e1403. doi: 10.1371/journal.pntd.0001403. Epub 2011 Dec 20. PLoS Negl Trop Dis. 2011. Retraction in: PLoS Negl Trop Dis. 2025 Jun 26;19(6):e0013229. doi: 10.1371/journal.pntd.0013229. PMID: 22206023 Free PMC article. Retracted.
References
Publication types
LinkOut - more resources
Full Text Sources